We are analyzing https://link.springer.com/article/10.1007/s12032-011-9855-6.

Title:
Second-line chemotherapy in metastatic docetaxel-resistant prostate cancer: a review | Medical Oncology
Description:
The results of cytotoxic therapy in the second-line setting of metastatic castration-resistant prostate cancer have demonstrated that disease is poorly controlled after taxane resistance with a time to progression of 3 months or less. Many trials of second-line chemotherapy have been disappointing. However, most of patients with docetaxel-pretreated castration-resistant disease receive a second-line chemotherapy. Molecular mechanism of castration resistance and docetaxel resistance is resumed, and clinical trials of second-line chemotherapy after docetaxel progression are reviewed. Reintroduction of docetaxel after a drug-free interval is an active treatment in docetaxel-pretreated patients, and only recently a prospective study documented a survival benefit of 2.4 months after second-line taxane-based chemotherapy of metastatic docetaxel-resistant prostate cancer. Although a second-line chemotherapy with a taxane could improve overall survival, a change of biology of castration-resistant prostate cancer after docetaxel is suggested, as inferred by the renewed hormonal sensitivity, whose role on survival remains unknown, and from the activity of antiangiogenic drugs.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,626,432 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure if the website is profiting.

While many websites aim to make money, others are created to share knowledge or showcase creativity. People build websites for various reasons. This could be one of them. Link.springer.com might be cashing in, but we can't detect the method they're using.

Keywords {🔍}

cancer, prostate, google, scholar, article, pubmed, docetaxel, cas, chemotherapy, patients, oncol, phase, castrationresistant, metastatic, study, clin, secondline, hormonerefractory, therapy, mitoxantrone, prednisone, trial, refractory, abstract, combination, proc, genitourinary, cancers, symposium, poster, session, treatment, survival, crpc, androgenindependent, androgen, randomized, hormone, oncology, docetaxelresistant, results, resistance, advanced, urol, res, ryan, colloca, progression, docetaxelpretreated, receptor,

Topics {✒️}

month download article/chapter castration-resistant prostate cancer hormone-resistant prostate cancer hormone-refractory prostate cancer castrate-resistant prostate cancer androgen-independent prostate cancer absolute prostate-specific antigen docetaxel-refractory prostate cancer docetaxel-resistant breast cancer anti-il-6 monoclonal antibody metastatic castration-resistant continued androgen-deprivation therapy double-blinded randomized comparison metastatic prostate cancer 2nd/3rd line therapy drug-free interval randomised open-label trial initial docetaxel-based chemotherapy 1st-line docetaxel therapy giuseppe colloca metastatic tumor growth de bono js primary prostate cancer weekly high-dose calcitriol advanced prostate cancer docetaxel/carboplatin-based chemotherapy full article pdf line taxane-based chemotherapy related subjects article colloca clin prostate cancer castration-resistance crpc privacy choices/manage cookies androgen ablation therapy secondary hormonal therapy androgen receptor mutations androgen receptor antagonists human prostate carcinoma docetaxel-based therapy author information authors cancer chemother pharmacol genes potentially involved castration resistance strong independent predictor high-dose calcitriol canadian randomized trial docetaxel-based chemotherapy taxane-based chemotherapy clin cancer res prior taxane therapy

Questions {❓}

Chemotherapy in androgen-independent prostate cancer (AIPC): what’s next after taxane progression?
First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Second-line chemotherapy in metastatic docetaxel-resistant prostate cancer: a review
         description:The results of cytotoxic therapy in the second-line setting of metastatic castration-resistant prostate cancer have demonstrated that disease is poorly controlled after taxane resistance with a time to progression of 3 months or less. Many trials of second-line chemotherapy have been disappointing. However, most of patients with docetaxel-pretreated castration-resistant disease receive a second-line chemotherapy. Molecular mechanism of castration resistance and docetaxel resistance is resumed, and clinical trials of second-line chemotherapy after docetaxel progression are reviewed. Reintroduction of docetaxel after a drug-free interval is an active treatment in docetaxel-pretreated patients, and only recently a prospective study documented a survival benefit of 2.4 months after second-line taxane-based chemotherapy of metastatic docetaxel-resistant prostate cancer. Although a second-line chemotherapy with a taxane could improve overall survival, a change of biology of castration-resistant prostate cancer after docetaxel is suggested, as inferred by the renewed hormonal sensitivity, whose role on survival remains unknown, and from the activity of antiangiogenic drugs.
         datePublished:2011-02-20T00:00:00Z
         dateModified:2011-02-20T00:00:00Z
         pageStart:776
         pageEnd:785
         sameAs:https://doi.org/10.1007/s12032-011-9855-6
         keywords:
            Castration-resistance
            Chemotherapy
            Docetaxel
            Prostate cancer
            Oncology
            Hematology
            Pathology
            Internal Medicine
         image:
         isPartOf:
            name:Medical Oncology
            issn:
               1559-131X
               1357-0560
            volumeNumber:29
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Giuseppe Colloca
               affiliation:
                     name:“Giovanni Borea” Hospital
                     address:
                        name:Division of Medical Oncology, “Giovanni Borea” Hospital, Sanremo, Italy
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Antonella Venturino
               affiliation:
                     name:“Giovanni Borea” Hospital
                     address:
                        name:Division of Medical Oncology, “Giovanni Borea” Hospital, Sanremo, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Franco Checcaglini
               affiliation:
                     name:ASL-1 Umbria
                     address:
                        name:Department of Radiotherapy, ASL-1 Umbria, Città di Castello, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Second-line chemotherapy in metastatic docetaxel-resistant prostate cancer: a review
      description:The results of cytotoxic therapy in the second-line setting of metastatic castration-resistant prostate cancer have demonstrated that disease is poorly controlled after taxane resistance with a time to progression of 3 months or less. Many trials of second-line chemotherapy have been disappointing. However, most of patients with docetaxel-pretreated castration-resistant disease receive a second-line chemotherapy. Molecular mechanism of castration resistance and docetaxel resistance is resumed, and clinical trials of second-line chemotherapy after docetaxel progression are reviewed. Reintroduction of docetaxel after a drug-free interval is an active treatment in docetaxel-pretreated patients, and only recently a prospective study documented a survival benefit of 2.4 months after second-line taxane-based chemotherapy of metastatic docetaxel-resistant prostate cancer. Although a second-line chemotherapy with a taxane could improve overall survival, a change of biology of castration-resistant prostate cancer after docetaxel is suggested, as inferred by the renewed hormonal sensitivity, whose role on survival remains unknown, and from the activity of antiangiogenic drugs.
      datePublished:2011-02-20T00:00:00Z
      dateModified:2011-02-20T00:00:00Z
      pageStart:776
      pageEnd:785
      sameAs:https://doi.org/10.1007/s12032-011-9855-6
      keywords:
         Castration-resistance
         Chemotherapy
         Docetaxel
         Prostate cancer
         Oncology
         Hematology
         Pathology
         Internal Medicine
      image:
      isPartOf:
         name:Medical Oncology
         issn:
            1559-131X
            1357-0560
         volumeNumber:29
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Giuseppe Colloca
            affiliation:
                  name:“Giovanni Borea” Hospital
                  address:
                     name:Division of Medical Oncology, “Giovanni Borea” Hospital, Sanremo, Italy
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Antonella Venturino
            affiliation:
                  name:“Giovanni Borea” Hospital
                  address:
                     name:Division of Medical Oncology, “Giovanni Borea” Hospital, Sanremo, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Franco Checcaglini
            affiliation:
                  name:ASL-1 Umbria
                  address:
                     name:Department of Radiotherapy, ASL-1 Umbria, Città di Castello, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Medical Oncology
      issn:
         1559-131X
         1357-0560
      volumeNumber:29
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:“Giovanni Borea” Hospital
      address:
         name:Division of Medical Oncology, “Giovanni Borea” Hospital, Sanremo, Italy
         type:PostalAddress
      name:“Giovanni Borea” Hospital
      address:
         name:Division of Medical Oncology, “Giovanni Borea” Hospital, Sanremo, Italy
         type:PostalAddress
      name:ASL-1 Umbria
      address:
         name:Department of Radiotherapy, ASL-1 Umbria, Città di Castello, Italy
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Giuseppe Colloca
      affiliation:
            name:“Giovanni Borea” Hospital
            address:
               name:Division of Medical Oncology, “Giovanni Borea” Hospital, Sanremo, Italy
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Antonella Venturino
      affiliation:
            name:“Giovanni Borea” Hospital
            address:
               name:Division of Medical Oncology, “Giovanni Borea” Hospital, Sanremo, Italy
               type:PostalAddress
            type:Organization
      name:Franco Checcaglini
      affiliation:
            name:ASL-1 Umbria
            address:
               name:Department of Radiotherapy, ASL-1 Umbria, Città di Castello, Italy
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Division of Medical Oncology, “Giovanni Borea” Hospital, Sanremo, Italy
      name:Division of Medical Oncology, “Giovanni Borea” Hospital, Sanremo, Italy
      name:Department of Radiotherapy, ASL-1 Umbria, Città di Castello, Italy
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(199)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

4.51s.

LINK . SPRINGER . COM {}